Harvard Apparatus Regenerative (HART) 2.92 $HART
HART prices public offering
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 9:43AM CST
HART: 2.92 (+0.34)
Harvard Apparatus Regenerative Technology, Inc. Announces Pricing of Public Offering of Common Stock and Series B Convertible Preferred Stock
Business Wire - Thu Feb 12, 7:45AM CST
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ: HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, today announced the pricing of its previously announced underwritten public offering. HART is offering 1,800,000 registered shares of its common stock at a price to the public of $1.75 per share, and 695,857 registered shares of its Series B Convertible Preferred Stock ("Series B"
at a price to the public of $8.75 per share, for expected gross proceeds of approximately $9.2 million. At the option of the investor, the Series B is convertible into five shares of common stock of the Company, and will vote with the common stock on all matters on an as converted basis. The Series B has no preference to the common shares in respect of dividends, voting, liquidation or otherwise. In connection with the offering, HART has also granted the underwriter a 30-day option to purchase up to an additional 270,000 shares of common stock offered in the public offering to cover over-allotments, if any. HART intends to use the net proceeds from the offering primarily for research and development, including funding pre-clinical and clinical trials relating to the HART-Trachea, business development, sales and marketing, capital expenditures, working capital and other general corporate purposes.
HART: 2.92 (+0.34)
HART initiates equity offering
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 3:28PM CST
HART: 2.92 (+0.34)
Harvard Apparatus Regenerative Technology, Inc. Announces Proposed Public Offering of Common Stock and Series B Convertible Preferred Stock
Business Wire - Wed Feb 11, 3:20PM CST
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ: HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, today announced that it is proposing to offer shares of its common stock and Series B Convertible Preferred Stock ("Series B" in an underwritten public offering. At the option of the investor, the Series B is convertible into five shares of common stock of the Company, and will vote with the common stock on all matters on an as converted basis. The Series B has no preference to the common shares in respect of dividends, voting, liquidation or otherwise. HART expects to grant the underwriter a 30-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering to cover over-allotments, if any. HART intends to use the net proceeds from the offering primarily for research and development, including funding pre-clinical and clinical trials relating to the HART-Trachea, business development, sales and marketing, capital expenditures, working capital and other general corporate purposes. The final terms of the offering will depend on market and other conditions at the time of pricing, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
HART: 2.92 (+0.34)
Market Maker Surveillance Report. TBIO, PSTI, STRI, DWTI, HART, ARDX, Losing Stocks With Lowest Price Friction For Monday, February 2nd 2015
M2 - Tue Feb 03, 3:14AM CST
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 5214 companies with "abnormal" market making, 3994 companies with positive Friction Factors and 2396 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Monday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Transgenomic Inc (OTC:TBIO), Pluristem Therapeutics Inc (NASDAQ
STI), STR Holdings Inc New (NYSE:STRI), (NYSE
WTI), (NASDAQ:HART), (NASDAQ:ARDX). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
PSTI: 2.91 (+0.01), TBIO: 2.91 (+0.01), HART: 2.92 (+0.34), ARDX: 17.14 (+0.71), STRI: 1.65 (+0.04), DWTI: 95.90 (-7.40)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 11:49AM CST
FRO: 2.96 (+0.07), LUNA: 1.48 (-0.01), NES: 3.52 (+0.13), PSTI: 2.91 (+0.01), MILL: 2.07 (+0.09), TBIO: 2.91 (+0.01), SONS: 17.69 (-0.01), NKA: 1.68 (+0.13), YOD: 2.22 (+0.04), ARDX: 17.14 (+0.71), SR: 1.25 (+0.08), OHGI: 1.82 (-0.12), LBIX: 3.43 (-0.06), DQ: 21.04 (-0.21), CLRX: 1.84 (+0.04), PSTR: 4.63 (+0.14), HART: 2.92 (+0.34), WAC: 20.29 (+2.57), CRK: 6.09 (+0.46), SRT: 8.85 (+0.07)
HART and Mayo Clinic Collaborate on Regenerated Trachea, Esophagus and Heart Valve
Business Wire - Wed Jan 07, 7:30AM CST
Harvard Apparatus Regenerative Technology, Inc., (NASDAQ: HART), or HART, has signed a joint development agreement with Mayo Clinic with the intent of developing and improving regenerative medicine treatments for severe diseases.
HART: 2.92 (+0.34)
Harvard Apparatus Regenerative Technology To Present at Biotech Showcase 2015 in San Francisco
Business Wire - Tue Jan 06, 10:14AM CST
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ: HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, will present at Biotech Showcase(TM) 2015 in San Francisco on Wednesday, January 14, 2015. David Green, CEO of Harvard Apparatus Regenerative Technology, will provide an overview of the company, its clinical developments and milestones.
HART: 2.92 (+0.34)
Harvard Apparatus Regenerative Technology Schedules Investor Teleconference for December 23, 2014, at 11:00 A.M. ET
Business Wire - Mon Dec 22, 1:19PM CST
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ: HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, will hold a conference call to discuss recent events at 11:00 AM (Eastern Time) on December 23, 2014. On that call, management may take questions from the audience on any of a number of topics related to the business, including operations, plans and outlook.
HART: 2.92 (+0.34)
Harvard Apparatus backs out of Russia
Seeking Alpha - at Seeking Alpha - Wed Nov 26, 7:23AM CST
HART: 2.92 (+0.34)
Harvard Apparatus Regenerative Technology No Longer Supporting Studies in Russia; Will Continue Focus on Preclinical Processes in the U.S. and EU
Business Wire - Wed Nov 26, 6:30AM CST
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), or HART, a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea announced that it will no longer be providing its HART-Trachea product for future transplant procedures performed at Krasnodar, Russia as part of the ongoing airway transplant studies there. HART will continue to focus primarily on completing preclinical work necessary to initiate clinical trials for its HART-Trachea product in the EU and U.S. It has made recent progress in the U.S. and EU, including the granting of orphan designation by the U.S. Food and Drug Administration (FDA) and a productive meeting with the Medicines and Healthcare Products Regulatory Agency of the U.K. (MHRA, the equivalent of the FDA in the U.K.). HART anticipates that during 2015 it will file its Investigational New Drug application to initiate a U.S. clinical trial and a Clinical Trial Authorization application to initiate an EU clinical trial.
HART: 2.92 (+0.34)
I'm Selling Harvard Apparatus Regenerative Technology
Jim Royal, The Motley Fool - Motley Fool - Tue Nov 18, 8:27AM CST
It's time to sell Harvard Apparatus Regenerative Technology . My Special Situations portfolio acquired shares in the speculative research and development company before it was spun off from Harvard Bioscience last year. Why sell? In...
HBIO: 5.31 (-0.01), HART: 2.92 (+0.34)
Harvard Apparatus Regenerative Technology misses by $0.01
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 6:46AM CST
HART: 2.92 (+0.34)
Harvard Apparatus Regenerative Technology Reports Operating Results for the Third Quarter Ended September 30, 2014
Business Wire - Thu Nov 06, 6:01AM CST
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq:HART), or HART, a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, reports unaudited financial results for the three and nine months ended September 30, 2014.
HART: 2.92 (+0.34)
The Company That Can Grow You A New Organ: A Promising Long-Term Investment
Daniel Kohlsdorf - Seeking Alpha - Thu Oct 30, 10:37AM CDT
About the company and its opportunities Harvard Apparatus Regenerative Technology (NASDAQ: HART ) makes the equipment used to create a new human trachea (breathing pipe) using the patient's own bone marrow cells. People who currently need a...
HBIO: 5.31 (-0.01), HART: 2.92 (+0.34)
HART reports November 6
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 11:01AM CDT
HART: 2.92 (+0.34)
Harvard Apparatus Regenerative Technology Schedules Release of Third Quarter 2014 Financial Results and Investor Teleconference for November 6, 2014
Business Wire - Mon Oct 27, 6:00AM CDT
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, will announce results of its third quarter ended September 30, 2014 before market trading hours on Thursday, November 6, 2014. A conference call to discuss the company's third quarter results and the company's operations is scheduled for that same day at 11:00 AM (Eastern Time). On that call, management may take questions from the audience on any of a number of topics related to the business, including operations, plans and outlook.
HART: 2.92 (+0.34)
Harvard Apparatus Regenerative Technology Updates Patient Status
Business Wire - Fri Oct 17, 7:30AM CDT
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq:HART), or HART, a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, has recently been informed by the principal investigator in the Russian regenerated trachea transplant studies in which it is taking part that one of the patients in that study has recently passed away. The Company has not been informed of the cause of death. The patient survived more than two years from the initial regenerated trachea transplant surgery that took place in 2012. Prior to that surgery, the patient had suffered several instances of life threatening respiratory failure and infections. The patient was indicated for the initial transplant surgery because there was both a progression of the respiratory failure and traditional tracheal surgery was impossible.
HART: 2.92 (+0.34)
Harvard Apparatus Regenerative Technology Obtains Orphan Drug Designation from U.S. Food and Drug Administration for HART-Trachea
Business Wire - Fri Sep 05, 1:51PM CDT
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), or HART, a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the HART-Trachea, which is intended to replace or repair a trachea that has been severely damaged by either trachea cancer or physical trauma.
HART: 2.92 (+0.34)
HART prices public offering
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 9:43AM CST
HART: 2.92 (+0.34)
Harvard Apparatus Regenerative Technology, Inc. Announces Pricing of Public Offering of Common Stock and Series B Convertible Preferred Stock
Business Wire - Thu Feb 12, 7:45AM CST
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ: HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, today announced the pricing of its previously announced underwritten public offering. HART is offering 1,800,000 registered shares of its common stock at a price to the public of $1.75 per share, and 695,857 registered shares of its Series B Convertible Preferred Stock ("Series B"
at a price to the public of $8.75 per share, for expected gross proceeds of approximately $9.2 million. At the option of the investor, the Series B is convertible into five shares of common stock of the Company, and will vote with the common stock on all matters on an as converted basis. The Series B has no preference to the common shares in respect of dividends, voting, liquidation or otherwise. In connection with the offering, HART has also granted the underwriter a 30-day option to purchase up to an additional 270,000 shares of common stock offered in the public offering to cover over-allotments, if any. HART intends to use the net proceeds from the offering primarily for research and development, including funding pre-clinical and clinical trials relating to the HART-Trachea, business development, sales and marketing, capital expenditures, working capital and other general corporate purposes. HART: 2.92 (+0.34)
HART initiates equity offering
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 3:28PM CST
HART: 2.92 (+0.34)
Harvard Apparatus Regenerative Technology, Inc. Announces Proposed Public Offering of Common Stock and Series B Convertible Preferred Stock
Business Wire - Wed Feb 11, 3:20PM CST
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ: HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, today announced that it is proposing to offer shares of its common stock and Series B Convertible Preferred Stock ("Series B"
in an underwritten public offering. At the option of the investor, the Series B is convertible into five shares of common stock of the Company, and will vote with the common stock on all matters on an as converted basis. The Series B has no preference to the common shares in respect of dividends, voting, liquidation or otherwise. HART expects to grant the underwriter a 30-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering to cover over-allotments, if any. HART intends to use the net proceeds from the offering primarily for research and development, including funding pre-clinical and clinical trials relating to the HART-Trachea, business development, sales and marketing, capital expenditures, working capital and other general corporate purposes. The final terms of the offering will depend on market and other conditions at the time of pricing, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. HART: 2.92 (+0.34)
Market Maker Surveillance Report. TBIO, PSTI, STRI, DWTI, HART, ARDX, Losing Stocks With Lowest Price Friction For Monday, February 2nd 2015
M2 - Tue Feb 03, 3:14AM CST
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 5214 companies with "abnormal" market making, 3994 companies with positive Friction Factors and 2396 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Monday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Transgenomic Inc (OTC:TBIO), Pluristem Therapeutics Inc (NASDAQ
STI), STR Holdings Inc New (NYSE:STRI), (NYSE WTI), (NASDAQ:HART), (NASDAQ:ARDX). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net . PSTI: 2.91 (+0.01), TBIO: 2.91 (+0.01), HART: 2.92 (+0.34), ARDX: 17.14 (+0.71), STRI: 1.65 (+0.04), DWTI: 95.90 (-7.40)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 11:49AM CST
FRO: 2.96 (+0.07), LUNA: 1.48 (-0.01), NES: 3.52 (+0.13), PSTI: 2.91 (+0.01), MILL: 2.07 (+0.09), TBIO: 2.91 (+0.01), SONS: 17.69 (-0.01), NKA: 1.68 (+0.13), YOD: 2.22 (+0.04), ARDX: 17.14 (+0.71), SR: 1.25 (+0.08), OHGI: 1.82 (-0.12), LBIX: 3.43 (-0.06), DQ: 21.04 (-0.21), CLRX: 1.84 (+0.04), PSTR: 4.63 (+0.14), HART: 2.92 (+0.34), WAC: 20.29 (+2.57), CRK: 6.09 (+0.46), SRT: 8.85 (+0.07)
HART and Mayo Clinic Collaborate on Regenerated Trachea, Esophagus and Heart Valve
Business Wire - Wed Jan 07, 7:30AM CST
Harvard Apparatus Regenerative Technology, Inc., (NASDAQ: HART), or HART, has signed a joint development agreement with Mayo Clinic with the intent of developing and improving regenerative medicine treatments for severe diseases.
HART: 2.92 (+0.34)
Harvard Apparatus Regenerative Technology To Present at Biotech Showcase 2015 in San Francisco
Business Wire - Tue Jan 06, 10:14AM CST
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ: HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, will present at Biotech Showcase(TM) 2015 in San Francisco on Wednesday, January 14, 2015. David Green, CEO of Harvard Apparatus Regenerative Technology, will provide an overview of the company, its clinical developments and milestones.
HART: 2.92 (+0.34)
Harvard Apparatus Regenerative Technology Schedules Investor Teleconference for December 23, 2014, at 11:00 A.M. ET
Business Wire - Mon Dec 22, 1:19PM CST
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ: HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, will hold a conference call to discuss recent events at 11:00 AM (Eastern Time) on December 23, 2014. On that call, management may take questions from the audience on any of a number of topics related to the business, including operations, plans and outlook.
HART: 2.92 (+0.34)
Harvard Apparatus backs out of Russia
Seeking Alpha - at Seeking Alpha - Wed Nov 26, 7:23AM CST
HART: 2.92 (+0.34)
Harvard Apparatus Regenerative Technology No Longer Supporting Studies in Russia; Will Continue Focus on Preclinical Processes in the U.S. and EU
Business Wire - Wed Nov 26, 6:30AM CST
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), or HART, a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea announced that it will no longer be providing its HART-Trachea product for future transplant procedures performed at Krasnodar, Russia as part of the ongoing airway transplant studies there. HART will continue to focus primarily on completing preclinical work necessary to initiate clinical trials for its HART-Trachea product in the EU and U.S. It has made recent progress in the U.S. and EU, including the granting of orphan designation by the U.S. Food and Drug Administration (FDA) and a productive meeting with the Medicines and Healthcare Products Regulatory Agency of the U.K. (MHRA, the equivalent of the FDA in the U.K.). HART anticipates that during 2015 it will file its Investigational New Drug application to initiate a U.S. clinical trial and a Clinical Trial Authorization application to initiate an EU clinical trial.
HART: 2.92 (+0.34)
I'm Selling Harvard Apparatus Regenerative Technology
Jim Royal, The Motley Fool - Motley Fool - Tue Nov 18, 8:27AM CST
It's time to sell Harvard Apparatus Regenerative Technology . My Special Situations portfolio acquired shares in the speculative research and development company before it was spun off from Harvard Bioscience last year. Why sell? In...
HBIO: 5.31 (-0.01), HART: 2.92 (+0.34)
Harvard Apparatus Regenerative Technology misses by $0.01
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 6:46AM CST
HART: 2.92 (+0.34)
Harvard Apparatus Regenerative Technology Reports Operating Results for the Third Quarter Ended September 30, 2014
Business Wire - Thu Nov 06, 6:01AM CST
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq:HART), or HART, a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, reports unaudited financial results for the three and nine months ended September 30, 2014.
HART: 2.92 (+0.34)
The Company That Can Grow You A New Organ: A Promising Long-Term Investment
Daniel Kohlsdorf - Seeking Alpha - Thu Oct 30, 10:37AM CDT
About the company and its opportunities Harvard Apparatus Regenerative Technology (NASDAQ: HART ) makes the equipment used to create a new human trachea (breathing pipe) using the patient's own bone marrow cells. People who currently need a...
HBIO: 5.31 (-0.01), HART: 2.92 (+0.34)
HART reports November 6
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 11:01AM CDT
HART: 2.92 (+0.34)
Harvard Apparatus Regenerative Technology Schedules Release of Third Quarter 2014 Financial Results and Investor Teleconference for November 6, 2014
Business Wire - Mon Oct 27, 6:00AM CDT
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, will announce results of its third quarter ended September 30, 2014 before market trading hours on Thursday, November 6, 2014. A conference call to discuss the company's third quarter results and the company's operations is scheduled for that same day at 11:00 AM (Eastern Time). On that call, management may take questions from the audience on any of a number of topics related to the business, including operations, plans and outlook.
HART: 2.92 (+0.34)
Harvard Apparatus Regenerative Technology Updates Patient Status
Business Wire - Fri Oct 17, 7:30AM CDT
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq:HART), or HART, a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, has recently been informed by the principal investigator in the Russian regenerated trachea transplant studies in which it is taking part that one of the patients in that study has recently passed away. The Company has not been informed of the cause of death. The patient survived more than two years from the initial regenerated trachea transplant surgery that took place in 2012. Prior to that surgery, the patient had suffered several instances of life threatening respiratory failure and infections. The patient was indicated for the initial transplant surgery because there was both a progression of the respiratory failure and traditional tracheal surgery was impossible.
HART: 2.92 (+0.34)
Harvard Apparatus Regenerative Technology Obtains Orphan Drug Designation from U.S. Food and Drug Administration for HART-Trachea
Business Wire - Fri Sep 05, 1:51PM CDT
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), or HART, a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the HART-Trachea, which is intended to replace or repair a trachea that has been severely damaged by either trachea cancer or physical trauma.
HART: 2.92 (+0.34)
